Antibodies

29 Jun 2008 Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
25 Jun 2008 IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient Enrollment
25 Jun 2008 CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
25 Jun 2008 Genmab Initiates Study of Zalutumumab with Radiotherapy in Head and Neck Cancer
24 Jun 2008 Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
19 Jun 2008 Amgen and Wyeth Statement on Outcome of Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting
19 Jun 2008 Merck Applies to Extend Use of Erbitux for First-Line Head and Neck Cancer in Europe
18 Jun 2008 ThromboGenics and BioInvent announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody
18 Jun 2008 FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
18 Jun 2008 Biotie's VAP-1 Antibody Program to Proceed to Clinical Studies in Rheumatoid Arthritis and Psoriasis Patients
17 Jun 2008 Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease
17 Jun 2008 Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
16 Jun 2008 OncoMed Pharmaceuticals Extends License Agreement for Use of MorphoSys's Core Technology
16 Jun 2008 Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITP
15 Jun 2008 New data reveals Actemra is the first and only biologic drug to show superiority over current standard of care in rheumatoid arthritis
15 Jun 2008 Data from Phase II Exploratory Study Suggest That ORENCIA(R) (abatacept) May Delay Development of Rheumatoid Arthritis in Adults with Undifferentiated Inflammatory Arthritis
15 Jun 2008 New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
15 Jun 2008 Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
15 Jun 2008 HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis with Combination Treatment Resulted in Cost Savings From Improved Work Productivity
12 Jun 2008 Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
12 Jun 2008 ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
11 Jun 2008 Ofatumumab in subcutaneous study in rheumatoid arthritis
11 Jun 2008 Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
10 Jun 2008 Symphogen Enters into strategic collaboration with Genentech for antibody thera-peutics
09 Jun 2008 Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top